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studies directly comparing two modalities are required to defineSustained low-efficiency dialysis for critically ill patients requir-
the exact role for SLED in this setting.ing renal replacement therapy.
Background. The replacement of renal function for critically
ill patients is procedurally complex and expensive, and none
of the available techniques have proven superiority in terms The extracorporeal replacement of renal function forof benefit to patient mortality. In hemodynamically unstable or
critically ill patients is managed by the complementaryseverely catabolic patients, however, the continuous therapies
techniques of conventional intermittent hemodialysishave practical and theoretical advantages when compared with
conventional intermittent hemodialysis (IHD). (IHD) and continuous renal replacement therapies
Methods. We present a single center experience accumu- (CRRTs). To date, neither technique has proven superi-
lated over 18 months since July 1998 with a hybrid technique ority in terms of benefit to patient mortality (abstract;named sustained low-efficiency dialysis (SLED), in which stan-
Mehta et al, J Am Soc Nephrol 5:7, 1996) [1–3], anddard IHD equipment was used with reduced dialysate and
selection for a given patient is usually based on the clini-blood flow rates. Twelve-hour treatments were performed noc-
turnally, allowing unrestricted access to the patient for daytime cal situation, clinician proficiency with the technique,
procedures and tests. and logistic capabilities of the institution and intensive
Results. One hundred forty-five SLED treatments were per- care unit (ICU)/dialysis personnel [4, 5].
formed in 37 critically ill patients in whom IHD had failed or
There are relative advantages and disadvantages tobeen withheld. The overall mean SLED treatment duration
IHD and CRRTs. IHD is the more traditional techniquewas 10.4 hours because 51 SLED treatments were prematurely
discontinued. Of these discontinuations, 11 were for intractable and is familiar to most nephrologists and nursing person-
hypotension, and the majority of the remainder was for extra- nel. Modern IHD machinery allows for precise volumet-
corporeal blood circuit clotting. Hemodynamic stability was ric ultrafiltration control and online bicarbonate dialy-
maintained during most SLED treatments, allowing the achieve- sate production. IHD is rendered feasible by virtue ofment of prescribed ultrafiltration goals in most cases with an
high intradialytic solute clearances, which allow for briefoverall mean shortfall of only 240 mL per treatment. Direct
treatment times and easy access to patients for out-of-dialysis quantification in nine patients showed a mean delivered
double-pool Kt/V of 1.36 per (completed) treatment. Mean phos- unit diagnostic and therapeutic procedures. However,
phate removal was 1.5 g per treatment. Mild hypophosphatemia the ultrafiltration of substantial fluid volumes over short
and/or hypokalemia requiring supplementation were observed treatment times is frequently associated with hemody-
in 25 treatments. Observed hospital mortality was 62.2%, which
namic instability in critically ill patients, thus limiting thewas not significantly different from the expected mortality as
removal of obligatory fluid loads [6]. Ironically, despitedetermined from the APACHE II illness severity scoring
system. high intradialytic solute clearances, the dose of dialysis
Conclusions. SLED is a viable alternative to traditional con- delivered in acute renal failure (ARF) tends to be low
tinuous renal replacement therapies for critically ill patients in compared with targets established for end-stage renal
whom IHD has failed or been withheld, although prospective
disease (ESRD; abstract; Jaber et al, J Am Soc Nephrol
8:284A, 1997) [7], and this may be relevant to patient
outcome (abstract; Schiffl et al, J Am Soc Nephrol 8:290A,Key words: continuous veno-venous hemodialysis, acute renal failure,
critical care medicine, intermittent hemodialysis, SLED, kidney failure. 1997) [8]. Furthermore, with IHD, solute control is peri-
odic, and subsequent disequilibrium and water shifts may
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moval [3, 10–12] and improved steady-state azotemia tion was prescribed to allow for gradual fluid removal,
to provide good solute clearance based on animal experi-control even for severely catabolic patients [13]. How-
ever, implementation of a CRRT program is expensive ments [18, 19], and to coincide with ICU nursing shifts.
The Fresenius 2008H [Fresenius Medical Care Northbecause of costs related to specialized machinery, filters
and lines, and filtrate replacement fluid [10, 14]. Logisti- America (FMC-NA), Lexington, MA, USA] was utilized
without additional software or hardware with standardcally, CRRTs may be unfamiliar to many nephrologists
[15] and also result in increased workload for already lines and F8 low flux polysulfone (FMC-NA) hemodia-
lyzers. Angioaccess was established with central venousbusy intensive care nurses. CRRTs are frequently inter-
rupted with out-of-unit diagnostic and therapeutic proce- hemodialysis catheters. In the absence of contraindica-
tion, patients were systemically anticoagulated with un-dures, which leads to a reduction in dialysis dose from
“down time,” as well as the expense and inconvenience fractionated heparin to prevent extracorporeal blood cir-
cuit clotting. A loading dose of heparin was given at thefrom unscheduled extracorporeal blood circuitry re-
placement [16]. Furthermore, there is a definite need for initiation of a SLED treatment and/or an infusion (100
IU/mL) into the extracorporeal blood circuit proximalcontinuous anticoagulation during CRRTs to prevent
extracorporeal blood circuit clotting [6]. to the hemodialyzer. Heparinization was guided by serial
measurement of the activated partial thromboplastinPreliminary reports have emerged from several centers
concerning hybrid techniques that utilize standard IHD time (APTT), which was drawn peripherally and tar-
geted to be 1.5 times control. Online dialysate was gener-equipment, but have therapeutic aims in common with
CRRTs, that is, lower solute clearances maintained for ated with a bicarbonate proportioning system using tap
water treated with a reverse osmosis (RO) system. Theprolonged periods of time (abstracts; Chatoth at al, Blood
Purif 17:16, 1999; and Hu et al, Blood Purif 17:15, 1999) QD of 100 mL/min allowed a canister of dialysate concen-
trate to last the entire treatment without replacement[17]. We hypothesized that the ideal renal replacement
therapy for critically ill patients would be characterized (maximum 17 hours). Dialysate composition was var-
ied according to clinical needs, but the default dialysateby (1) adequate solute control, (2) precise achievement
of ultrafiltration goals without hypotension, (3) satisfac- contained [K] of 4.0 mEq/L, [HCO3] of 35 mmol/L,
and [Ca2] of 2.5 mEq/L.tory patient outcomes, (4) high acceptance by nursing
personnel, (5) procedural simplicity and low cost, and (6) Minor adjustments were necessary to the operating
parameters of the 2008H in a service mode. The QD ofnocturnal scheduling allowing unrestricted patient access
for daytime procedures and tests. These principles have 100 mL/min required activation of the “slow dialysis”
option. Prior to the initiation of SLED, recalibration ofprovided the rationale for the development of a dialysis
technique named sustained low-efficiency dialysis (SLED), the temperature control to 37C at a QD of 100 mL/min
was necessary to avoid persistent low dialysate tempera-which was introduced in July 1998 at the University of
Arkansas for Medical Sciences (UAMS). We present ture alarms. Although not mandatory for the perfor-
mance of SLED with the 2008H, new CRRT softwarehere a detailed description of our experience accumu-
lated over 18 months. is available that eliminates the need for recalibration
and includes a dedicated screen for CRRT for a clearer
interface with the nurse managing the treatment.
METHODS
Patient selection Logistic considerations
At the inception of the SLED program, treatmentsAll critically ill patients requiring renal replacement
therapy were considered for SLED. Clinician determina- were deliberately scheduled during the day to allow ICU
nurses to become familiar with the SLED procedure. Intion defined the need for renal replacement therapy
based on standard indications. SLED treatments were 1999, with the program firmly established, treatments
were largely nocturnal (75% of treatment start timesperformed for patients in whom IHD (1) had repeatedly
failed (therapy termination before 50% completion) due between 1600 and 2400 h), reflecting the original ratio-
nale and intention for SLED.to intradialytic hypotension unresponsive to increased
inotropic support and/or resuscitative fluid administra- The nephrology team assumed medical responsibility
for SLED. Prescription and objectives of SLED were gen-tion, (2) had been withheld because of clinician determi-
nation that hemodynamic intolerance was likely, and erally discussed and endorsed by both nephrology and the
ICU medical staff. Interrupted treatments were some-(3) had failed to achieve overall goals in solute control
despite daily IHD. times re-initiated by the on-call dialysis nurse after con-
sultation with the responsible nephrologist. Treatments
Technical considerations could be discontinued at the discretion of the nephrolo-
gist if therapeutic objectives had been achieved by theDefault dialysate (QD) and blood flow (QB) rates were
set at 100 and 200 mL/min, respectively. A 12-hour dura- time of the interruption. SLED continued to be utilized
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until patients were hemodynamically stable enough to deaths and the number of expected hospital deaths from
the APACHE II model within each 10% stratum of thebe managed with IHD. Generally, patients were treated
with daily or alternate-day SLED according to clinical cohort’s expected risk of death. Hospital mortality ratios
and 95% confidence intervals (regarding observed mor-need.
Protocols were developed to establish operational pro- tality as a binomial variable) were obtained by dividing
the observed by expected hospital mortality [24].cedures and to define relative responsibilities between
the ICU and dialysis nursing personnel. The dialysis Unless otherwise stated, the results are expressed
mean  SD (range). Means were compared by the Stu-nurse educator was responsible for training all of the
ICU nursing personnel. Dialysis nurses were responsible dent t test. All SLED patients and treatments were evalu-
ated on an intention-to-treat basis.for the provision and initiation of SLED treatments,
while troubleshooting and discontinuation responsibilit-
Laboratory methodsies were shared. The ICU nurses performed hourly moni-
toring and documentation and management of machine Blood and dialysate solutes were monitored at two
hourly intervals during a single SLED treatment in con-alarms according to simple algorithms. The dialysis
nurses were always available in house or from home for senting patients. A blood sample was collected at one-
hour post-SLED, at which time solute equilibrium wasadvice and assistance to the ICU nurse.
assumed (abstract; Lo et al, J Am Soc Nephrol 8:287A,
Evaluation of SLED 1997) [25]. Chemical analyses were performed in tripli-
cate by multianalyzer (Dade Dimension Flex ClinicalThe study protocol was approved by the UAMS Hu-
man Research Advisory Committee, and informed con- Chemistry Systems, Newark, DE, USA). Total dialysate
collection was undertaken using serially arranged sterilesent was obtained from all patients in accordance with the
guidelines proposed in the Declaration of Helsinki [20]. 15 L peritoneal dialysis cycler effluent bags (Baxter
Healthcare Corporation, Deerfield, IL, USA). BloodA single-center SLED registry was instituted in July
1998, and data were prospectively collected by MD inves- (from the hemodialysis catheter at QB 0) and dialysate
were collected by a single investigator (M.M.) at strictlytigators and entered into an Access-based (Microsoft
Corporation, Seattle, WA, USA) relational database for timed intervals. All samples were immediately processed
(blood) or immediately frozen at 70F for later testingfuture analysis. Patient data collection included demo-
graphic characteristics, primary and renal diagnoses, and (dialysate). Plasma water was assumed to be 93% of
plasma volume, and this factor was used to convert serumoutcomes. Treatment data collection included ultrafiltra-
tion volumes, patient vital signs, inotropic agent require- to plasma water concentrations for dialysate-based ki-
netic calculations. Dialysate phosphate determinationsments, and details of SLED prescription. Complications
noted by nursing or medical staff at the time of SLED were performed in triplicate [Dade Dimension clinical
chemistry system, intra-assay coefficient of variationwere also reviewed and logged.
Illness severity was determined for each patient by (CV) 1.4%, inter-assay CV 3.6%] to estimate the total
phosphate removal. Dialysate urea nitrogen determina-the APACHE II scoring system [21]. The use of this
system for outcome prediction was originally validated tions were performed in triplicate (Dade Dimension
Clinical Chemistry System; intra-assay CV 2.6%, in-in prospective multicenter studies, utilizing scores that
were calculated from physiological measurements at the terassay CV 4.8%) to estimate the total urea nitrogen
removal, and double-pool Kt/V using urea kinetic mod-time of ICU admission. More recently, the APACHE II
scoring system also has been validated in a prospective els (UKM) based on dialysate collection theory (Appen-
dix) [26].multicenter fashion for patients specifically with ARF,
but with scores determined at the time of dialysis initia-
tion [22, 23]. Accordingly, two APACHE II scores were
RESULTS
calculated for each patient in our cohort, the first from
Patient characteristicsphysiological variables obtained during the first 24 hours
of ICU admission and the second from those obtained Sustained low-efficiency dialysis treatments were per-
formed in 37 patients whose clinical profiles are providedduring the 24 hours before the initiation of dialytic treat-
ment in the ICU. Expected hospital mortality rates for in Table 1. Median age was 58 years. Five patients were
primarily managed by the cardiovascular service, 6 bythe APACHE II scores were calculated using the logistic
regression calculations suggested in the original article to surgery, and 21 by internal medicine. Eighteen patients
did not have a history of underlying renal disease,adjust for the initial admitting diagnosis. The predictive
capacity of the APACHE II model in the SLED patient whereas 19 had chronic renal impairment with a baseline
serum creatinine value 1.4 mg/dL. Four of these hadcohort (goodness-of-fit) was assessed by the Hosmer-
Lemeshow statistic. This statistic measures the corre- ESRD. Fifty-one SLED treatments were performed in
patients while they were anuric. In the remainder, urinespondence between the number of observed hospital
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Table 1. Clinical characteristics of 37 patients treated with sustained low efficiency dialysis (SLED)
Age-racea-sexb Inotropes/PPVc Diagnosis Outcomed
72-B-M / Myocardial infarction; urosepsis; prostate cancer D
39-B-F / Sepsis; disseminated head and neck cancer D
55-W-M / Sepsis; MMe; s/p BMT f A
32-W-F / End-stage CHFg; s/p CABGh MVRi D
87-W-M / Sepsis; MM; s/p chemotherapy A
41-B-F / Multitrauma D
43-B-M / End-stage CHF; s/p cardiac arrest A
40-B-F / Fulminant hepatic failure; MM; ESRD A
66-W-M / Sepsis; disseminated lung cancer D
74-W-M / Pancreatitis; pneumonia D
65-W-M / Sepsis; colonic infarction; infected aortic prosthesis D
72-B-F / Sepsis; pneumonia A
45-W-M / Sepsis; end-stage liver disease; rhabdomyolysis A
50-W-M / Sepsis; end-stage CHF; MM D
55-B-F / Sepsis; ESRD A
74-W-F / Sepsis; MM; s/p chemotherapy A
82-W-F / Sepsis; colonic perforation; ESRD D
79-W-F / Sepsis; colonic perforation A
46-B-M / Sepsis; bacterial endocarditis; severe burns D
71-W-M / Sepsis; MM; s/p BMT D
60-W-M / Sepsis; disseminated lung cancer A
80-W-M / Sepsis; s/p CABG D
59-W-M / Sepsis; end-stage liver disease D
70-W-M / Sepsis; colonic infarction; s/p CABG  MVR D
61-W-M / Ehrlichiosis; rhabdomyolysis A
57-W-M / Sepsis; MM; s/p BMT D
71-W-M / Sepsis; MM; s/p BMT A
25-W-M / Vasulitis; rhabdomyolysis A
78-W-M / Sepsis; s/p CABG  MVR D
83-W-M / End-stage CHF D
47-W-F / End-stage CHF; MM; ESRD A
31-W-F / Sepsis; MM; s/p chemotherapy D
35-W-F / Sepsis; MM; s/p BMT D
52-B-M / Sepsis; MM; s/p chemotherapy D
58-B-M / Sepsis; end-stage liver disease D
71-W-M / Sepsis; colonic perforation; myocardial infarction D
56-W-M / Sepsis; end-stage CHF; s/p CABG MVR D
a Results are given as B (black), H (Hispanic), W (white)
b Results are given as M (male), F (female)
c Positive pressure ventilation (PPV)
d Results are given as A (alive at hospital discharge), D (dead during hospitalization)
e Multiple myeloma (MM)
f Bone marrow transplant (BMT)
g Congestive heart failure (CHF)
h Coronary artery bypass grafting (CABG)
i Mitral valve replacement (MVR)
output was 234.8  368.8 (3 to 1748) mL/day. Of 145 pacity of the APACHE II model to predict hospital
mortality in the SLED patient cohort is graphically dis-SLED treatments, 117 were performed for patients re-
ceiving concurrently administered nutrition (47% intra- played in Figures 1 and 2. Goodness-of-fit statistics are
associated with high P values (suggesting a good fit).venous, 30% enteral, and 4% combined).
In two patients, the indication for SLED was failure Hospital mortality ratios are provided in Table 3 and
indicate that the number of observed hospital deathsof solute control despite daily IHD. In 35 patients, the
indication for SLED was hemodynamic intolerance to was not significantly different from that expected from
the APACHE II scores.IHD, despite the ubiquitous use of inotropic agents and
resuscitative intravenous fluids. Of this latter group, 23
SLED characteristicspatients failed a trial of IHD, whereas in the remainder
IHD had been withheld because of clinician determina- A total of 145 SLED treatments were performed. The
median number of SLED treatments per patient wastion that hemodynamic intolerance was likely. Table 2
compares hemodynamic profiles, inotropic agent re- two (range 1 to 30, mean  SD, 3.9  6.1). The median
number of patient days during which SLED was per-quirements, and illness severity scores between the pa-
tients with actual versus anticipated failure of IHD. formed without interruption by IHD was two (range 1
to 66, mean  SD, 7.5  14.1). Prescribed blood flowThe observed hospital mortality was 62.2%. The ca-
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Table 2. Actual versus anticipated intermittent hemodialysis (IHD) patients
Parameter Actual Anticipated
Number of patientsa 23 12
Pre-SLED MAP 72.516.3 (40.7–112.0) 67.69.3 (49.0–86.0)
Pre-SLED pulse 100.218.7 (68.0–154.0) 97.819.6 (70.0–127.0)
Inotrope number at first SLEDc 0.91.0 (0.0–4.0) 2.00.9 (1.0–3.0)
Organs failed (ICU admission) 4.51.4 (1.0–7.0) 5.01.3 (2.0–6.0)
Organs failed (dialytic initiation) 5.31.3 (3.0–7.0) 6.00.9 (5.0–7.0)
APACHE II score (ICU admission) 27.88.2 (12.0–55.0) 31.811.7 (11.0–46.0)
APACHE II expected mortality (ICU admission) 62.621.4 (15.0–99.0) 70.228.8 (14.0–96.0)
APACHE II score (dialytic initiation)b 30.18.2 (19.0–52.0) 35.77.6 (21.0–45.0)
APACHE II expected mortality (dialytic initiation)b 68.823.6 (19.0–99.0) 82.716.7 (42.0–97.0)
Results are given as mean  SD (range).
a The indication for SLED was hemodynamic instability in 35 patients
b P  0.05 actual vs. anticipated Student t test (two-tailed)
Fig. 1. Patient outcome prediction by APACHE II score at admission Fig. 2. Patient outcome prediction by APACHE II score at the initia-
tion of dialysis in the ICU. Expected () versus observed ( ) hospitalto intensive care unit (ICU). Expected () versus observed ( ) hospital
deaths for 37 patients treated with sustained low-efficiency dialysis deaths for 37 patients treated with SLED from July 1998 to January
2000 (2  6.1, P  0.53).(SLED) from July 1998 to January 2000 (2  1.54, P  0.96).
rate was 201.1  7.5 (200 to 250) mL/min, and all treat- to 11.75) hours for the 51 prematurely discontinued treat-
ments.ments were performed with dialysate flow at 100 mL/
min. Dialysate potassium concentrations varied from 2
Hemodynamic stability(2% of treatments) to 4 (62% of treatments) mEq/L,
and calcium concentrations varied from 1.7 (1% of treat- Mean arterial pressure (MAP) pre-SLED was 69.1 
13.8 (40.7 to 119.7) mm Hg, and post-SLED was 68.9 ments) to 3.0 (5% of treatments) mEq/L, with the major-
ity being 2.5 mEq/L. 16.7 (39.0 to 113.0, P  0.26) mm Hg. Pulse pre-SLED
was 99.0  15.6 (63.0 to 154.0) per minute, and post-Fifty-one (34.5%) SLED treatments were prematurely
discontinued. Twenty-nine (20%) were discontinued for SLED was 101.2  16.4 (59.0 to 157.0). This increase
in pulse during SLED of 2.2  11.5 per minute wasextracorporeal blood circuit clotting and 11 (7.6%) for
intractable hypotension. The remaining treatments were statistically significant (P 0.05). Core temperature pre-
SLED was 37.0C  0.7C (34.3C to 38.8C), and post-discontinued for miscellaneous problems, which included
RO leak, machine or angioaccess failure, arrhythmia, SLED was 37.0C  0.6C (35.0C to 38.8C, P  0.17).
Inotropic agents were concurrently administered dur-withdrawal of therapy, massive gastrointestinal bleeding,
emergent surgery, and death secondary to acute pericar- ing 27 of the 35 treatments where SLED was performed
for the first time in patients who had previously beendial tamponade. The overall SLED treatment duration
was 10.41  2.73 (0.5 to 12) hours and 7.56  2.88 (0.5 hemodynamically intolerant to IHD. Eighty of the over-
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Table 3. Expected outcomes of patients treated with SLED
Expected hospital mortality %a Hospital mortality ratiob
APACHE II (ICU admission) 66.325.6 (14.0–99.0) 0.92 (0.78–1.22)
APACHE II (dialytic initiation) 74.123.1 (19.0–99.0) 0.83 (0.70–1.00)
Thirty-seven patients were treated with SLED between July 1998 and January 2000.
a Results are given as mean  SD (range)
b Results are given as parameter (95% confidence intervals)
all 145 SLED treatments were in patients receiving ino- performed in patients already anticoagulated for other
indications. In these cases, a decision was made to defertropic agents. The median number of concurrently ad-
ministered inotropic agents per patient pre-SLED was the prescription of additional anticoagulant with SLED.
The remaining 96 treatments were performed with con-one (range 1 to 4, mean  SD, 1.4  0.7), and this did
not change significantly post-SLED (median 1, range currently administered unfractionated heparin. An ex-
tracorporeal circuit infusion at a rate of 481.1  290.51 to 3, mean , SD 1.4  0.7). However, half of the
inotropically supported patients underwent an increase (100 to 1400) IU/h was used for all of these treatments,
whereas a loading dose [1884.6  1431.1 (1000 to 6000)in inotrope dose (median 66.7%, range 0 to 500%, mean
SD, 98  105.5%), and three treatments required an IU] was given at SLED initiation only for 13 treatments.
During heparinized treatments, the maximum recordedadditional inotropic agent for hemodynamic stability.
Twenty-five SLED treatments were associated with one APTT was 52.3 30.4 sec (13.7 to 120 sec) as compared
with the immediate pre-SLED APTT of 47.0  22.0 secor more episodes of hypotension (defined as the need for
resuscitative intravenous fluids 250 mL per treatment (22.1 to 120 sec) in the heparin-free group (P  0.29).
Extracorporeal blood-circuit clotting occurred in 38and/or modification of ultrafiltration goals). The problem
was insurmountable in 11 of these treatments, leading to SLED treatments. Nine of these 38 treatments were re-
premature discontinuation of SLED. Post-SLED MAP in initiated, and the rest were discontinued at the discretion
these treatments was 48.9  7.4 (39 to 61) mm Hg. of the nephrologist. Neither the administration of hepa-
Prescribed ultrafiltration per treatment was 3.0  1.4 rin with SLED [odds ratio 0.80 (95% CI, 0.53 to 1.21)]
(0 to 6) L. The achieved ultrafiltration per treatment was nor anticoagulation by other means [odds ratio 0.83
2.8  1.5 (0 to 6) L after correction for the treatments (95% CI, 0.56 to 1.23)] was statistically associated with
was abandoned because of extracorporeal blood circuit a lower probability of circuit clotting. APTTs, interna-
clotting, machine failure, and other miscellaneous causes. tional normalized ratios (INRs), and platelet counts were
not significantly different between SLED treatments that
Small solute clearances clotted and those that did not.
Nine oligoanuric (urine output150 mL/24 h) patients Bleeding complicated 2 out of 145 SLED treatments.
underwent total dialysate collection, and all successfully The first episode (hemorrhagic pericardial tamponade
completed their prescribed SLED treatments. Total dial- within 48 hours of coronary artery bypass grafting) oc-
ysate urea nitrogen removal was 28.6  10.9 (12.7 to curred in the absence of any anticoagulant, while the
43.8) g per treatment, and double-pool Kt/V was 1.36  second (massive hemorrhage from multiple previously
0.38 (0.86 to 2.08). Dialysate phosphate removal was 1.5 unrecognized upper gastrointestinal ulcers) occurred six
0.6 (0.8 to 2.5) g per treatment. Of the total urea nitrogen hours after heparinization specifically for SLED.
and phosphate removal, 24.4  2.6% (20.6 to 27.0%)
and 26.9  2.6% (22.5 to 34.4%), respectively, occurred
DISCUSSIONin the last four hours of SLED treatment.
A total of 145 SLED treatments were performed inComparisons of pre- and post-SLED solutes are
37 patients over the 18-month study period. The patientsshown in Table 4. Significant changes were seen in potas-
were critically ill, with expected hospital mortality ratessium, creatinine, blood urea nitrogen, venous bicarbon-
that were similar to those previously reported for patientsate, phosphate, and total calcium. Hypokalemia in the
with multiorgan failure undergoing CRRTs [10, 27]. All12 hours following SLED was noted in seven treatments,
had either failed IHD or were justifiably anticipated torequiring supplementation of 41.4 14.6 (20 to 60) mEq.
do so. In general, SLED was a safe, effective, and conve-Similarly, 18 SLED treatments resulted in PO4 supple-
nient renal replacement therapy in these patients.mentation of 21.3  7.5 (10 to 40) mmol.
There is concern that hypotension during renal re-
Anticoagulation placement therapy may be detrimental to renal recovery
(abstract; Manns et al, ASAIO J 42:78, 1996) [28]. ManyForty-one SLED treatments were performed without
anticoagulation. Of the remaining 104 treatments, 8 were retrospective studies have suggested that CRRTs are
Marshall et al: SLED for critically ill patients 783
Table 4. Solute changes pre- and post-SLED in 9 patients undergoing completed SLED treatments
Solute Pre-SLED Post-SLED 60 min P value
Sodium mEq/L 137.64.1 (129–143) 136.73.4 (131–142) 0.5
Potassium mEq/L 4.60.8 (3.4–5.7) 3.90.5 (3.4–4.5) 0.02
Venous bicarbonate mEq/L 20.36.5 (7–28) 24.43.2 (18–28) 0.02
BUN mg/dL 71.625.5 (30–109) 31.011.5 (16–47) 0.0001
Creatinine mg/dL 3.42.0 (1.7–8.2) 1.60.8 (0.8–3.5) 0.003
Total calcium mg/dL 7.91.2 (5.7–9.8) 8.71.4 (7.0–10.8) 0.005
Phosphate mg/dL 5.92.1 (3.5–9.5) 3.41.0 (2.3–5.0) 0.0003
Albumin g/dL 2.21.1 (1.0–3.5) 2.31.3 (1.0–3.9) 0.8
Results are given as meanSD (range); P values are by the paired Student t test (one-tailed).
superior to IHD in terms of hemodynamic stability (ab- performed in approximately 30% of cases. Heparin ad-
stract; Manns et al, J Am Soc Nephrol 6: 470, 1995) [3, ministration in the remaining treatments usually con-
10–12], and a single prospective study in dispute of this sisted of an extracorporeal circuit infusion without an
has been criticized for methodological flaws [29]. How- initial loading dose. The percentage of heparin-free dial-
ever, it is clear that hemodynamic instability can still ysis in our series is higher than has been reported with
occur with hemofiltration if fluid removal is too large or CRRTs [33], and it is conceivable that a more aggressive
rapid, and previous investigators have reported higher anticoagulation protocol could have resulted in less clot-
rates of hypotension with intermittent rather than con- ting, but possibly more bleeding complications.
tinuous hemofiltration [30]. SLED was hemodynamically Sustained low-efficiency dialysis provided adequate
tolerated in most patients, and precise achievement of small solute clearances and an acceptable dialysis dose.
ultrafiltration goals was possible in most cases. However, The ability for SLED to provide adequate clearances
hypotension did occur during several SLED treatments despite low blood flow rates makes it an appealing option
and necessitated SLED discontinuation in 7.6% of treat- for patients with marginally functional temporary ac-
ments. Patients on inotropic agents often needed an in- cesses. SLED prescription could be varied in clinical
crease in dose for hemodynamic support during SLED, situations to suit the goals for clearance on an individual
and this may have contributed to cardiac dysrhythmia basis. Serious electrolyte disturbances did not occur, but
in one patient. However, these findings must be consid- some patients needed phosphate and potassium supple-
ered in the context that these patients had already dem- mentation. Electrolytes need to be closely monitored,
onstrated intolerance to IHD. Three of the 11 patients especially if SLED is performed on a daily basis.
who were persistently hypotensive with SLED were sub- For both traditional CRRTs and SLED, responsibilit-
sequently treated with continuous venovenous hemofil- ies are shared between ICU and dialysis nurses, and the
tration (CVVH), and all were hemodynamically intoler-
success of such programs is critically dependent on the
ant to this therapy as well. Conceivably, hemodynamic
skills and training of ICU nurses [5]. SLED has beenstability during SLED may be improved by lengthening
well accepted by ICU nursing staff and is simpler thanthe treatment duration, although in our experience, hy-
CVVH to manage at a nursing level (abstract; Hall etpotension that did not necessitate the discontinuation
al, Blood Purif 17:36, 1999). Because of the decreasedof SLED was easily treated, and increases in inotropic
nursing workload, the patient to ICU nurse ratio is 2:1support only transient. Since treatment failure with
for SLED compared with the 1:1 ratio often requiredSLED due to hypotension was predictive of failure with
for CRRTs. The transition to nocturnal scheduling hasCVVH, we do not plan to change our duration of SLED
been successful and is convenient in allowing unrestrictedprotocol. However, if in individual patients increasing
patient access for daytime procedures and tests. Further-the SLED duration is helpful, we would recommend that
more, at UAMS the same 2008H equipment has beenapplication.
used for conventional IHD during the day and thenComplications associated with SLED were common
SLED at night. The use of the 2008H for SLED allows forto all CRRTs. Extracorporeal blood circuit clotting oc-
considerable savings in an initial equipment investmentcurred in approximately 25% of SLED treatments prior
when compared with traditional CRRTs. A program ofto completion. For CRRTs, APTT is a good predictor
SLED is also less expensive to maintain than traditionalof filter clotting [31], and most opinion leaders recom-
CRRTs, regardless of machinery or replacement solutionsmend an APTT of 10 to 20 seconds above control [31, 32].
utilized (abstract; Alam et al, Am J Kidney Dis 35:A9,The high incidence of thrombocytopenia in our group
2000). In previous reports, considerable modifications(47% of patients with platelet counts less than 100,000/
have been necessary to enable existing hemodialysis ma-mm3 at SLED initiation) was a factor in the conservative
approach to anticoagulation. Heparin-free SLED was chines to provide CRRT [34], while in our current pro-
Marshall et al: SLED for critically ill patients784
tent hemodialysis in acute renal failure patients in the intensivegram, the new CRRT software allows the 2008H to be
care unit. ASAIO J 39:M778–M781, 1993quickly adapted between SLED and IHD. 2. Kresse S, Schlee H, Deuber H, et al: Influence of renal replace-
The duration of dialysis treatments may have a posi- ment therapy on outcome of patients with acute renal failure.
Kidney Int 56(Suppl 72):S75–S78, 1999tive impact on survival in critically ill patients with ARF,
3. Bellomo R, Farmer M, Parkin G, et al: Severe acute renal failure:and SLED could have a role in the treatment of such
A comparison of acute continuous hemodiafiltration and conven-
patients irrespective of their hemodynamic stability. Pro- tional dialytic therapy. Nephron 71:59–64, 1995
4. Bellomo R, Ronco C: Continuous versus intermittent renal re-spective studies directly comparing SLED to traditional
placement therapy in the intensive care unit. Kidney Int 53(SupplCRRTs will help define the exact role for SLED in the
66):S125–S128, 1998critical care setting, although a leading indication would 5. Lameire N, Van Biesen W, Vanholder R: Dialysing the patient
be in acute dialysis programs where traditional CRRTs with acute renal failure in the ICU: The emperor’s clothes? Nephrol
Dial Transplant 14:2570–2573, 1999are unavailable. In conclusion, our recent experience
6. Mehta R: Continuous renal replacement therapies in the acutesuggests that SLED is a viable alternative to traditional
renal failure setting: Current concepts. Adv Ren Replace Ther 4:81–
CRRTs as renal replacement in critically ill patients in 92, 1997
7. Evanson J, Himmelfarb J, Wingard R, et al: Prescribed versuswhom IHD had previously failed or been withheld.
delivered dialysis in acute renal failure. Am J Kidney Dis 32:731–
738, 1998ACKNOWLEDGMENTS
8. Paganini EP, Tapolyai M, Goormastic M, et al: Establishing a
dialysis therapy/patient outcome link in intensive care unit acuteThis work was supported in part by unrestricted educational grants
dialysis for patients with acute renal failure. Am J Kidney Disfrom Bristol-Myers Squibb Company (New York, NY, USA), and
Merck & Co., Inc. (West Point, PA, USA). The authors gratefully 28(Suppl 3):S81–S89, 1996
acknowledge the following people: the nurses of the acute hemodialysis 9. Davenport A, Finn R, Goldsmith H: Management of patients
unit at UAMS for their help in establishing the SLED program (particu- with renal failure complicated by cerebral oedema. Blood Purif
larly Ms. Anne Hall, Ms. Linda Owens, and Ms. Melissa Bixler); Dr. 7:203–209, 1988
Laurie Garred for his expert advice; Dr. Christian Schlaeper for his 10. Van Bommel E, Bouvy N, So K, et al: Acute dialytic support
technical assistance; and Mr. David Ward and Ms. Frances Holmes for the critically ill: Intermittent hemodialysis versus continuous
for supplies. arteriovenous hemodiafiltration. Am J Nephrol 15:192–200, 1995
11. Wendon J, Smithies M, Sheppard M, et al: Continuous high volumeReprint requests to Dinesh K. Chatoth, M.D., Division of Nephrol-
venous-venous haemofiltration in acute renal failure. Intensiveogy, Department of Internal Medicine, University of Arkansas for Medi-
Care Med 15:358–363, 1989cal Sciences, 4301 West Markham, Slot 501, Little Rock, Arkansas 72205,
12. Stevens P, Riley B, Davies S, et al: Continuous arteriovenousUSA.
haemodialysis in critically ill patients. Lancet 2:150–152, 1988E-mail: chatothdineshk@exchange.uams.edu
13. Clark WR, Mueller BA, Kraus MA, Macias WL: Dialysis pre-
scription and kinetics in acute renal failure. Adv Ren Replace Ther
4(Suppl 1):64–71, 1997APPENDIX
14. Moreno L, Heyka R, Paganini E: Continuous renal replacement
Total urea removal (U) was determined by total dialysate collection. therapy: Cost considerations and reimbursement. Semin Dial
The following equations have been derived previously [26] and are 9:209–214, 1996
generated under the conditions of a variable-volume, double-pool urea 15. Mehta R, Letteri J: Current status of renal replacement therapy
kinetic model and KR 0. Urea equilibrium was assumed at 60 minutes for acute renal failure. Am J Nephrol 19:377–382, 1999post-SLED. Serum blood urea nitrogen (BUN) was divided by 0.93
16. Frankenfield D, Reynolds H, Wiles C, et al: Urea removalfor conversion to plasma urea nitrogen (PUN). Double-pool V were
during continuous hemodiafiltration. Crit Care Med 22:407–412,calculated from urea mass balance:
1993
Double-pool V 17. Schlaeper C, Amerling R, Manns M, Levin N: High clearance
continuous renal replacement therapy with a modified dialysis
machine. Kidney Int 65(Suppl 72):S20–S23, 1999
18. Kudoh Y, Iimura O: Slow continuous hemodialysis: New therapy
U  PUNpre 	 (BWpre  BSpost)  PUNnext 	
T  60

  60
	 (BWnext  BWpost)
PUNpre  PUNequil 
T  60

  60
	 (PUNnext  PUNequil) for acute renal failure in critically ill patients. I. Theoretical consid-
erations and new technique. Jpn Circ J 52:1171–1182, 1988
19. Kudoh Y, Shiiki M, Y, et al: Slow continuous hemodialysis: Newwhere T, 
, and BW refer to intradialytic time, interdialytic time, and
therapy for acute renal failure in critically ill patients. II. Animalbody weight, respectively, and the subscripts of pre, post, equil, and
experiments and clinical implication. Jpn Circ J 52:1183–1190, 1988next refer to pre-SLED values, post-SLED values, values 60 minutes
post-SLED, and values at the start of the following dialysis treatment 20. 48th World Medical Assembly: Declaration of Helsinki: Recom-
respectively. Double-pool G were calculated from classical UKM as mendations guiding physicians in biomedical research involving
proposed by Gotch et al: human subjects. JAMA 277:925–926, 1997
21. Knaus W, Draper E, Wagner D, Zimmermen J: APACHE II: ADouble-pool G
severity of disease classification system. Crit Care Med 13:818–829,
1985

PUNnext 	 (Double-pool V  BWnext  BWpost)  PUNequil 	 Double-pool V

  60 22. Brivet F, Kleinknecht D, Loirat P, Landais P: Acute renal failure
in intensive care units- causes, outcome, and prognostic factors ofDouble-pool K were estimated: hospital mortality: A prospective, multicentre study. Crit Care Med
24:192–198, 1996
23. Parker R, Himmelfarb J, Tolkoff-Rubin N, et al: Prognosis of
Double-pool K 
U
T  60
	
ln PUNprePUNequil
(PUNequil  PUNpre) patients with acute renal failure requiring dialysis: Results of a
multicenter study. Am J Kidney Dis 32:432–443, 1998
24. Morris J, Gardner M: Calculating confidence intervals for relativeREFERENCES
risks (odds ratios) and standardised ratios and rates. Br Med J
296:1313–1316, 19881. Kruczynski K, Irvine-Bird K, Toffelmire E, Morton A: A com-
parison of continuous arteriovenous hemofiltration and intermit- 25. Leblanc M, Tapolyai M, Paganini EP: What dialysis dose should
Marshall et al: SLED for critically ill patients 785
be provided in acute renal failure? A review. Adv Ren Replace critically ill patients with acute hepatic and renal failure. Crit Care
Med 21:328–338, 1993Ther 2:255–264, 1995
26. Garred L: Dialysate-based kinetic modeling. Adv Ren Replace 31. Van de Wetering J, Westerndorp R, van der Hoeven J, et al:
Heparin use in continuous renal replacement procedures: TheTher 2:305–318, 1995
27. Chertow G, Christiansen C, Cleary P, et al: Prognostic stratifica- struggle between filter coagulation and patient hemorrhage. J Am
Soc Nephrol 7:145–150, 1996tion in critically ill patients with acute renal failure requiring dial-
ysis. Arch Intern Med 155:1505–1511, 1995 32. Manns M, Sigler M, Teehan B: Continuous renal replacement
therapies: An update. Am J Kidney Dis 32:185–207, 199828. Conger J: Does hemodialysis delay recovery from acute renal
failure. Semin Dial 3:146–150, 1990 33. Martin P, Chevrolet J, Suter P, Favre H: Anticoagulation in
patients treated by continuous venovenous hemofiltration: A retro-29. Misset B, Timsit J-F, Chevret S, et al: A randomized cross-over
comparison of the hemodynamic response to intermittent hemodi- spective study. Am J Kidney Dis 24:806–812, 1994
34. Macias W, Mueller B, Scarim S, et al: Continuous venovenousalysis and continuous hemofiltration on ICU patients with acute
renal failure. Intensive Care Med 22:742–746, 1996 hemofiltration: An alternative to continuous arteriovenous hemo-
filtration and hemodiafiltration in acute renal failure. Am J Kidney30. Davenport A, Will E, Davidson A: Improved cardiovascular
stability during continuous modes of renal replacement therapy in Dis 18:451–458, 1991
